TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ROSEN, A LONGSTANDING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

Rosen Law Firm is investigating potential securities claims for Skye Bioscience investors, alleging the company made false and misleading statements about its drug nimacimab's effectiveness and prospects during the period of November 4, 2024 to October 3, 2025.

Insights
MSFT   positive

Established strategic multi-year GPU cloud services contract with IREN, indicating investment in AI infrastructure and cloud capabilities


SKYE   negative

The lawsuit alleges the company made materially false statements about its drug's effectiveness, clinical prospects, and commercial potential, suggesting intentional misrepresentation of the company's true status